Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31368203 | 0.81 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL28300188 | 0.80 | — | — | |
| SCHEMBL14361050 | 0.80 | — | — | |
| SCHEMBL8532055 | 0.80 | THRB (0.32) | — | |
| Hydrochloric Acid SCHEMBL31702677 | 0.80 | TSHR (0.34) | OPRM1 | |
| Hydrogen Sulfide SCHEMBL29062317 | 0.77 | THRB (0.30) | — | |
| SCHEMBL12674080 | 0.77 | OPRM1 (0.33) | OPRM1 | |
| Hydrochloric Acid SCHEMBL31094858 | 0.75 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL4024768 | 0.75 | — | — | |
| SCHEMBL732380 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037389-B | A kind of preparation method of rifamycin nitroimidazole coupling molecule | 丹诺医药(苏州）有限公司 | 2017-09-05 | — | — | CN | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-103596960-B | 6, 7-dihydroimidazo [2,1-B ] [1,3] oxazine fungicides | 大塚制药株式会社 | 2016-11-16 | — | — | CN | disclosed |
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | disclosed |
| CN-105037389-A | Preparation method of rifamycin-nitroiminazole coupled molecule | TENNOR THERAPEUTICS LTD | 2015-11-11 | — | — | CN | disclosed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2697232-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-19 | — | — | EP | disclosed |
| CN-103596960-A | 6, 7-dihydroimidazo [2,1-B ] [1,3] oxazine fungicides | OTSUKA PHARMA CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| WO-2012141338-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-18 | — | — | WO | disclosed |
| WO-2011090965-A1 | NOVEL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| CN-102083812-A | Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia | ASTRAZENECA AB | 2011-06-01 | — | — | CN | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-5238936-A | Antitumor agents, anticarcinogenic agents | ADIR ET COMPAGNIE (FR) | 1993-08-24 | — | — | US | disclosed |
| US-5225411-A | Triazines | ADIR ET COMPAGNIE (FR) | 1993-07-06 | — | — | US | disclosed |
| EP-0502788-A1 | Trisubstituted triazines and pyrimidines, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-09-09 | — | — | EP | disclosed |
| US-4514398-A | Disubstituted polymethylene imines | ADIR (FR) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | NPC1L1, CETP, LIPA | OPRM1 4670/4885 |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | OPRM1 1603/4885 |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | OPRM1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.